Water Thermodynamics of Peptide Toxin Binding Sites on Ion Channels
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Spider-Venom Peptides As Therapeutics
Toxins 2010, 2, 2851-2871; doi:10.3390/toxins2122851 OPEN ACCESS toxins ISSN 2072-6651 www.mdpi.com/journal/toxins Review Spider-Venom Peptides as Therapeutics Natalie J. Saez, Sebastian Senff, Jonas E. Jensen, Sing Yan Er, Volker Herzig, Lachlan D. Rash and Glenn F. King * Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland, 4072, Australia; E-Mails: [email protected] (N.J.S.); [email protected] (S.S.); [email protected] (J.E.J.); [email protected] (S.Y.E.); [email protected] (V.H.); [email protected] (L.D.R.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: 61-7-3346-2025; Fax: 61-7-3346-2021. Received: 16 November 2010; in revised form: 17 December 2010 / Accepted: 17 December 2010 / Published: 20 December 2010 Abstract: Spiders are the most successful venomous animals and the most abundant terrestrial predators. Their remarkable success is due in large part to their ingenious exploitation of silk and the evolution of pharmacologically complex venoms that ensure rapid subjugation of prey. Most spider venoms are dominated by disulfide-rich peptides that typically have high affinity and specificity for particular subtypes of ion channels and receptors. Spider venoms are conservatively predicted to contain more than 10 million bioactive peptides, making them a valuable resource for drug discovery. Here we review the structure and pharmacology of spider-venom peptides that are being used as leads for the development of therapeutics against a wide range of pathophysiological conditions including cardiovascular disorders, chronic pain, inflammation, and erectile dysfunction. -
Peptide Therapeutics Designing a Science-Led Strategic Quality Control Program
BioProcess International Peptide SPECIAL REPORT Therapeutics Designing a Science-Led Strategic Quality Control Program INTERTEK PHARMACEUTICAL SERVICES Your partner for regulatory-driven, phase appropriate analytical programs tailored to your molecule. Our experts help you to navigate the challenges of development, regulatory submission, and manufacturing. Peptide Therapeutics Designing a Science-Led Strategic Quality Control Program Shashank Sharma and Hannah Lee ince the emergence of peptide therapeutics in the 1920s with the advent of insulin therapy, the market for this product class has continued to expand with global revenues anticipatedS to surpass US$50 billion by 2024 (1). The growth of peptide therapeutics is attributed not only to improvements in manufacturing, but also to a rise in demand because of an increasingly aging population that is driving an increase in the occurrence of long-term diseases. The need for efficient and low-cost drugs and rising investments in research and development of novel drugs continues to boost market growth and fuel the emergence of generic versions that offer patients access to vital medicines at low costs. North America has been the dominant market for peptide therapeutics, with the Asia–Pacific region Insulin molecular model; the first therapeutic expected to grow at a faster rate. The global peptides use of this peptide hormone was in the market has attracted the attention of key players 1920s to treat diabetic patients. within the pharmaceutical industry, including Teva Pharmaceuticals, Eli Lilly, Novo Nordisk, Pfizer, amino acids to be peptides. Within that set, those Takeda, and Amgen. Those companies have made containing 10 or more are classed as polypeptides. -
Targeting Ion Channels in Cancer: a Novel Frontier in Antineoplastic Therapy A
66 Current Medicinal Chemistry, 2009, 16, 66-93 Targeting Ion Channels in Cancer: A Novel Frontier in Antineoplastic Therapy A. Arcangeli*,1, O. Crociani1, E. Lastraioli1, A. Masi1, S. Pillozzi1 and A. Becchetti2 1Department of Experimental Pathology and Oncology, University of Firenze, Italy; 2Department of Biotechnology and Biosciences, University of Milano-Bicocca, Italy Abstract: Targeted therapy is considerably changing the treatment and prognosis of cancer. Progressive understanding of the molecular mechanisms that regulate the establishment and progression of different tumors is leading to ever more spe- cific and efficacious pharmacological approaches. In this picture, ion channels represent an unexpected, but very promising, player. The expression and activity of different channel types mark and regulate specific stages of cancer progression. Their contribution to the neoplastic phenotype ranges from control of cell proliferation and apoptosis, to regulation of invasiveness and metastatic spread. As is being in- creasingly recognized, some of these roles can be attributed to signaling mechanisms independent of ion flow. Evidence is particularly extensive for K+ channels. Their expression is altered in many primary human cancers, especially in early stages, and they frequently exert pleiotropic effects on the neoplastic cell physiology. For instance, by regulating membrane potential they can control Ca2+ fluxes and thus the cell cycle machinery. Their effects on mitosis can also de- pend on regulation of cell volume, usually in cooperation with chloride channels. However, ion channels are also impli- cated in late neoplastic stages, by stimulating angiogenesis, mediating the cell-matrix interaction and regulating cell motil- ity. Not surprisingly, the mechanisms of these effects are manifold. -
Potent Neuroprotection After Stroke Afforded by a Double-Knot Spider-Venom Peptide That Inhibits Acid-Sensing Ion Channel 1A
Potent neuroprotection after stroke afforded by a double-knot spider-venom peptide that inhibits acid-sensing ion channel 1a Irène R. Chassagnona, Claudia A. McCarthyb,c, Yanni K.-Y. China, Sandy S. Pinedaa, Angelo Keramidasd, Mehdi Moblie, Vi Phamb,c, T. Michael De Silvab,c, Joseph W. Lynchd, Robert E. Widdopb,c, Lachlan D. Rasha,f,1, and Glenn F. Kinga,1 aInstitute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia; bBiomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia; cDepartment of Pharmacology, Monash University, Clayton, VIC 3800, Australia; dQueensland Brain Institute, The University of Queensland, St. Lucia, QLD 4072, Australia; eCentre for Advanced Imaging, The University of Queensland, St. Lucia, QLD 4072, Australia; and fSchool of Biomedical Sciences, The University of Queensland, St. Lucia, QLD 4072, Australia Edited by Solomon H. Snyder, Johns Hopkins University School of Medicine, Baltimore, MD, and approved February 6, 2017 (received for review September 1, 2016) Stroke is the second-leading cause of death worldwide, yet there are extracellular pH that occurs during cerebral ischemia. ASIC1a is the no drugs available to protect the brain from stroke-induced neuronal primary acid sensor in mammalian brain (9, 10) and a key mediator of injury. Acid-sensing ion channel 1a (ASIC1a) is the primary acid sensor stroke-induced neuronal damage. Genetic ablation of ASIC1a reduces in mammalian brain and a key mediator of acidosis-induced neuronal infarct size by ∼60% after transient middle cerebral artery occlusion damage following cerebral ischemia. Genetic ablation and selective (MCAO) in mice (7), whereas pharmacologic blockade with modestly pharmacologic inhibition of ASIC1a reduces neuronal death follow- potent ASIC1a inhibitors, such as amiloride (7) and nonsteroidal anti- ing ischemic stroke in rodents. -
Peptides As Drug Candidates: Limitations and Recent Development Perspectives
ISSN: 2574-1241 Volume 5- Issue 4: 2018 DOI: 10.26717/BJSTR.2018.08.001694 Yusuf A Haggaga. Biomed J Sci & Tech Res Mini Rewiew Open Access Peptides as Drug Candidates: Limitations and Recent Development Perspectives Yusuf A. Haggag*1, Ahmed A. Donia1,2, Mohamed A. Osman1, Sanaa A. El-Gizawy1 1Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta, Egypt 2Department of Pharmaceutical Technology, Faculty of Pharmacy, Menofia University, Menofia, Egypt Received: Published: *Corresponding August author: 28, 2018; September 05, 2018 Yusuf A Haggag, Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Egypt Abbreviations: GLP-1: Glucagon-Like Peptide-1; PEG: Polyethylene Glycol; Gamma IgG: Immunoglobulin; FcRn: Fc Receptor Introduction [4]. Discovery of several tumor-related peptides and proteins also Peptides can be defined as polypeptide chains of 50 or less protein/peptide receptors is supposed to create a new revolution amino acids or 5000 Da in molecular weight characterized by a wave of more promising, effective and selective anticancer drugs in high degree of secondary structure and lack of tertiary structure. the future. Therapeutic anticancer peptides will capture the largest Therapeutic peptides have traditionally been derived from nature share of the cancer therapeutic market [2]. This mode of cancer as naturally occurring peptide hormones (known as bioactive treatment including peptides, proteins and monoclonal antibodies peptides), genetic/recombinant libraries and chemical libraries is termed “biologics” treatment option [5]. [1]. The recent technologies used for peptides production include chemical synthesis, enzymatic synthesis, recombinant DNA About 75% from the whole peptide drugs in the market that biotechnology, cell-free expression and transgenic animal or plant gained total global sales over $1 billion are used directly in cancer There are several hundred peptide candidates under clinical species. -
ION CHANNELS S72 Acid-Sensing (Proton-Gated) Ion Channels (Asics) Alexander Et Al
ION CHANNELS S72 Acid-sensing (proton-gated) ion channels (ASICs) Alexander et al Acid-sensing (proton-gated) ion channels (ASICs) Overview: Acid-sensing ion channels (ASICs, provisional nomenclature) are members of a Na þ channel superfamily that includes the epithelial Na channel, ENaC, the FMRF-amide activated channel of Helix aspersa, the degenerins (DEG) of Caenorhabitis elegans (see Waldmann & Lazdunski, 1998; Mano & Discoll, 1999) and ‘orphan’ channels that include BLINaC (Sakai et al., 1999) and INaC (Schaefer et al., 2000). ASIC subunits contain two putative TM domains and assemble as homo- or heterotetramers to form proton-gated, Na þ permeable channels. Splice variants of ASIC1 (provisionally termed ASIC1a (ASIC-a) (Waldmann et al., 1997a) and ASIC1b (ASIC-b) (Chen et al., 1998)) and ASIC2 (provisionally termed ASIC2a (MDEG1) and ASIC2b (MDEG2); Lingueglia et al., 1997) have been cloned. Unlike ASIC2a (listed in table), heterologous expression of ASIC2b alone does not support H þ -gated currents. Transcripts encoding a fourth member of the ASIC family (ASIC4/SPASIC) do not produce a proton-gated channel in heterologous expression systems (Akopian et al., 2000; Grunder et al., 2000). ASIC channels are expressed in central and peripheral neurons and particularly in nociceptors where they participate in neuronal sensitivity to acidosis. The relationship of the cloned ASICs to endogenously expressed proton-gated ion channels is becoming established (Escoubas et al., 2000; Sutherland et al., 2001; Wemmie et al., 2002; 2003). Heterologously expressed heteromutimers of ASIC1/ASIC2a, ASIC2a/ASIC2b, ASIC2a/ASIC3 ASIC2b/ASIC3 and ASIC1a/ASIC3 form ion channels with altered kinetics, ion selectivity, pH-sensitivity and sensitivity to block by Gd3 þ (Bassilana et al., 1997; Lingueglia et al., 1997; Babinski et al., 2000; Escoubas et al., 2000). -
Design, Development, and Characterization of Novel Antimicrobial Peptides for Pharmaceutical Applications Yazan H
University of Arkansas, Fayetteville ScholarWorks@UARK Theses and Dissertations 8-2013 Design, Development, and Characterization of Novel Antimicrobial Peptides for Pharmaceutical Applications Yazan H. Akkam University of Arkansas, Fayetteville Follow this and additional works at: http://scholarworks.uark.edu/etd Part of the Biochemistry Commons, Medicinal and Pharmaceutical Chemistry Commons, and the Molecular Biology Commons Recommended Citation Akkam, Yazan H., "Design, Development, and Characterization of Novel Antimicrobial Peptides for Pharmaceutical Applications" (2013). Theses and Dissertations. 908. http://scholarworks.uark.edu/etd/908 This Dissertation is brought to you for free and open access by ScholarWorks@UARK. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of ScholarWorks@UARK. For more information, please contact [email protected], [email protected]. Design, Development, and Characterization of Novel Antimicrobial Peptides for Pharmaceutical Applications Design, Development, and Characterization of Novel Antimicrobial Peptides for Pharmaceutical Applications A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Cell and Molecular Biology by Yazan H. Akkam Jordan University of Science and Technology Bachelor of Science in Pharmacy, 2001 Al-Balqa Applied University Master of Science in Biochemistry and Chemistry of Pharmaceuticals, 2005 August 2013 University of Arkansas This dissertation is approved for recommendation to the Graduate Council. Dr. David S. McNabb Dissertation Director Professor Roger E. Koeppe II Professor Gisela F. Erf Committee Member Committee Member Professor Ralph L. Henry Dr. Suresh K. Thallapuranam Committee Member Committee Member ABSTRACT Candida species are the fourth leading cause of nosocomial infection. The increased incidence of drug-resistant Candida species has emphasized the need for new antifungal drugs. -
Therapeutic Oligos & Peptides
Focus on Therapeutic Oligos & Peptides Enhancing the pharmaceutical properties of peptides To begin the discussion about enhancing or improving pharmaceutical properties, one must fi rst understand “the good, the bad, and the ugly” of peptides (1). The good. Peptides are generally highly potent, selective, and have a low potential for toxicity and low risk of drug-drug interaction. The bad. Peptides are generally not terribly stable in biological matrices, susceptible to protease degradation. The ugly. The polar nature of the peptide bond and the size of peptide molecules makes permeability across cell membranes challenging. In small molecule drug PEGylation development, we commonly think PEGylation refers to the attachment about Lipinski’s rule of fi ve (2), of poly(ethylene glycol) or PEG to which is based on the observation Keyw ds peptides or proteins and is able that most orally administered drugs to improve the pharmacokinetic have common physicochemical PEGylation, lipidation, properties of these molecules. characteristics, namely, glycosylation, PEG increases the hydration shell 1. a molecular mass less than 500 cyclization, of a peptide, making the peptide daltons non-natural amino less susceptible to renal clearance 2. a logP (octanol-water partition acid substitution and protease degradation. coeffi cient) less than 5 PEGylation can also decrease the 3. no more than 5 hydrogen bond immunogenicity potential. There are donors many diff erent PEG molecules that can be covalently 4. no more than 10 (2 x 5) hydrogen bond acceptors. attached to peptides including linear or branched, low Peptides violate each and every one of these rules, molecular weight or high molecular weight. -
Pain Research Product Guide | Edition 2
Pain Research Product Guide | Edition 2 Chili plant Capsicum annuum A source of Capsaicin Contents by Research Area: • Nociception • Ion Channels • G-Protein-Coupled Receptors • Intracellular Signaling Tocris Product Guide Series Pain Research Contents Page Nociception 3 Ion Channels 4 G-Protein-Coupled Receptors 12 Intracellular Signaling 18 List of Acronyms 21 Related Literature 22 Pain Research Products 23 Further Reading 34 Introduction Pain is a major public health problem with studies suggesting one fifth of the general population in both the USA and Europe are affected by long term pain. The International Association for the Study of Pain (IASP) defines pain as ‘an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage’. Management of chronic pain in the clinic has seen only limited progress in recent decades. Treatment of pain has been reliant on, and is still dominated by two classical medications: opioids and non-steroidal anti-inflammatory drugs (NSAIDs). However, side effects such as dependence associated with opioids and gastric ulceration associated with NSAIDs demonstrates the need for new drug targets and novel compounds that will bring in a new era of pain therapeutics. Pain has been classified into three major types: nociceptive pain, inflammatory pain and neuropathic or pathological pain. Nociceptive pain involves the transduction of painful stimuli by peripheral sensory nerve fibers called nociceptors. Neuropathic pain results from damage or disease affecting the sensory system, and inflammatory pain represents the immunological response to injury through inflammatory mediators that contribute to pain. Our latest pain research guide focuses on nociception and the transduction of pain to the spinal cord, examining some of the main classical targets as well as emerging pain targets. -
Peptides: Drivers and Challenges
INTERVIEWGAYLE DE MARIA1*, BRUCE H. MORIMOTO2 *Corresponding author 1. Chimica Oggi - Chemistry Today / TKS Publisher 2. Celerion, Redwood City CA 94061, USA Member of Chimica Oggi / Chemistry Today Scientific Advisory Board Gayle De Maria The expansion of the therapeutic applications of peptides: drivers and challenges The notable expansion of peptide therapeutics in the late 1990s and 2000s led to an unprecedented number of marketing approvals in 2012, and has provided a robust pipeline that should deliver numerous approvals during the remaining decade (1). Peptides offer certain advantages as drugs; these include their high biological activity, high specificity and low toxicity. However, challenges exist for the drug development of peptide therapeutics. Obstacle number one: in general, peptides need to be parenterally delivered (via injection) because oral administration would lead to their degradation in the digestive tract. Obstacle number two: they have a short half-life because they are quickly broken down by proteolytic enzymes. Obstacle number three: their chemical nature prevents them to a large extent from getting past physiological barriers or membranes (2). That said, why has there been a renaissance with respect to peptide drugs in the pharmaceutical industry? First of all we should say that peptides often target receptors and enzymes that are difficult or impossible to access with small molecules; thereby, providing drug discovery and development of novel targets to potentially offset the revenue void left by recent drug failures and the loss of patent protection of blockbuster drugs. Moreover peptides can complement biologics as drugs with the hope for greater efficacy, selectivity and specificity. Peptides possess bioactivities that are of major interest for drug discovery; peptides, peptide fragments, or peptidometics can intervene in most physiological processes and pathways. -
Trypsin-Like Proteases and Their Role in Muco-Obstructive Lung Diseases
International Journal of Molecular Sciences Review Trypsin-Like Proteases and Their Role in Muco-Obstructive Lung Diseases Emma L. Carroll 1,†, Mariarca Bailo 2,†, James A. Reihill 1 , Anne Crilly 2 , John C. Lockhart 2, Gary J. Litherland 2, Fionnuala T. Lundy 3 , Lorcan P. McGarvey 3, Mark A. Hollywood 4 and S. Lorraine Martin 1,* 1 School of Pharmacy, Queen’s University, Belfast BT9 7BL, UK; [email protected] (E.L.C.); [email protected] (J.A.R.) 2 Institute for Biomedical and Environmental Health Research, School of Health and Life Sciences, University of the West of Scotland, Paisley PA1 2BE, UK; [email protected] (M.B.); [email protected] (A.C.); [email protected] (J.C.L.); [email protected] (G.J.L.) 3 Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University, Belfast BT9 7BL, UK; [email protected] (F.T.L.); [email protected] (L.P.M.) 4 Smooth Muscle Research Centre, Dundalk Institute of Technology, A91 HRK2 Dundalk, Ireland; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Trypsin-like proteases (TLPs) belong to a family of serine enzymes with primary substrate specificities for the basic residues, lysine and arginine, in the P1 position. Whilst initially perceived as soluble enzymes that are extracellularly secreted, a number of novel TLPs that are anchored in the cell membrane have since been discovered. Muco-obstructive lung diseases (MucOLDs) are Citation: Carroll, E.L.; Bailo, M.; characterised by the accumulation of hyper-concentrated mucus in the small airways, leading to Reihill, J.A.; Crilly, A.; Lockhart, J.C.; Litherland, G.J.; Lundy, F.T.; persistent inflammation, infection and dysregulated protease activity. -
The Role of Asic1a in the Regulation of Synaptic Release Probability
The Role of ASIC1a in the Regulation of Synaptic Release Probability THESIS Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University By Soluman Culver Graduate Program in Pathology The Ohio State University 2013 Master's Examination Committee: W. James Waldman, Adviser Candice Askwith John Enyeart Copyright by Soluman Culver 2013 Abstract Extracellular pH plays an important role in neuronal signaling. As primary receptors of pH signals, acid-sensing ion channels (ASICs) are able to translate fluctuations in the extracellular pH into membrane potentials and calcium signals. ASICs and pH signaling are thought to play important roles in anxiety, affect, and pain, although the mechanism by which they are able to influence these processes remains poorly understood. During conditions of dysregulated pH aberrant ASIC activity is known to result in cellular dysfunction and death, making a mechanistic explanation of ASIC function of broad importance to our understanding of downstream consequences during pathophysiological circumstances. One significant role of ASIC is in its ability to modulate synaptic vesicle release, a property which may contribute to neuronal dysfunction secondary to disruptions in pH signaling. This study demonstrates that the mechanism of ASIC-dependent regulation of synaptic vesicle does not rely upon rapid local signaling, but rather requires several hours of ASIC block to be interrupted, suggesting that it may take place through the induction of gene regulation and cause global changes in cellular physiology. Similarly, our results suggest that ASIC1a may be responding to endogenous proton flux to accomplish this regulation, refining our understanding of the cause and context of ASIC1a activation in health and disease.